Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

Hebei Medical University

China · Asia-Pacific

#746World rank of 1,038
36.3ICI scoreout of 100
#117National rank, of 169 in China
#233Regional rank, of 343 in Asia-Pacific
397.5Verified industry works, 2021 to 2025
155Company groups worked with (59 on two or more works)

Hebei Medical University is ranked #746 of 1,038. Its strongest pillar is durability (74): 19 of its company groups are sustained partners (five or more joint works in three or more of the five years). It is held back most by co-creation (20): 397.5 verified industry works against about 696 expected for its mix of fields; and by breadth (13): partners concentrated in a few research fields.

Research Collaboration Index 2026: #1012 of 1,195 · View the RCI profile →

Why this position

Four pillars, as percentiles

Co-creation30% of the score
20

How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 397.5 verified works against about 696 expected for its fields (0.57 times the expected rate).

Durability20% of the score
74

How much of its industry work sits in sustained partnerships with the same company group. 19 sustained partnerships: five or more joint works in three or more of the five years.

Scale30% of the score
42

The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 59 company groups on two or more joint works; 19 sustained partnerships.

Breadth20% of the score
13

How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.

Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (36.3) is the weighted average of the four percentiles. Rank 746 of 1,038 overall; 117 of 169 in China; 233 of 343 in Asia-Pacific. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →

In numbers

The evidence behind the position

2.7%of its 14,519 research works in 2021 to 2025 were co-authored with a verified company
0.57Industry co-authorship rate: 0.57 times what its mix of research fields would predict (397.5 verified works; about 696 expected)
19sustained partnerships: the same company group on five or more joint works in three or more of the five years

In China

117 of 169 ranked universities in China

  1. #115 Tianjin Medical University world #741, score 37.1
  2. #116 Guangzhou University of Chinese Medicine world #743, score 36.6
  3. #117 Hebei Medical University world #746, score 36.3
  4. #118 Northeast Agricultural University world #747, score 36.2
  5. #119 Chengdu University world #756, score 35.7

All ranked universities →   Asia-Pacific: 233 of 343 →

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Strongest sector positions

#188 of 638Pharmaceuticals and Therapeutics164 verified works in the sector
Pharmaceuticals and Therapeutics
164#188 of 638
Medical Technology and Digital Health
14under 20 works
Biotechnology and Advanced Therapies
13.5under 20 works
Artificial Intelligence
6.5under 20 works
Advanced Materials and Nanotechnology
2under 20 works
Clean Energy Transition
2under 20 works
Agriculture and Food Technology
1under 20 works
Not in any of the 21 sectors
194.5counted in the overall index

203 of its 397.5 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

Hebei Medical University co-authored verified work with 155 company groups, consortium papers aside: 59 of them on two or more works, and 19 as sustained partners.

The largest 12 of its 155 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
Jiangsu Hengrui MedicineChinaMedicine445 of 5
BGI GroupChinaBiochemistry, Genetics and Molecular Biology234 of 5
Shijiazhuang Yiling PharmaceuticalChinaMedicine175 of 5
TencentChinaComputer Science165 of 5
CSPC Pharmaceutical GroupChinaMedicine123 of 5
Siemens HealthineersGermanyMedicine11.54 of 5
Simcere PharmaceuticalChinaMedicine115 of 5
SiemensGermanyEngineering105 of 5
United Imaging HealthcareChinaMedicine9.55 of 5
Merck & Co. (MSD)United StatesMedicine93 of 5
SyngentaSTATE-OWNEDSwitzerlandMedicine84 of 5
Suzhou Zelgen Biopharmaceuticals Co.ChinaMedicine73 of 5

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Its most-cited verified works with 30 or fewer authors, leaving out guidelines and consensus statements. Citation counts are those of the open scholarly record at harvest. Each title links to the work.

Over time

Verified industry works by year

53.52021
592022
792023
98.52024
107.52025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

11 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT07492394 Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer with Jiangsu Hengrui Pharmaceutical Co., Ltd., 2025
  • NCT07153744 Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction with Shanghai Hutchison Pharmaceuticals Limited, 2025
  • NCT07004335 Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study with Qilu Pharmaceutical Co., Ltd., 2025
  • NCT07622446 Evaluate the Effectiveness and Safety of the OmniHeart 4.0 Percutaneous Ventricular Assist Device in Providing Hemodynamic Support for Patients Undergoing High-risk Percutaneous Coronary Intervention (PCI). with Shanghai Dynaheart Medtech Co., Ltd., 2024
  • NCT05818098 Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calcification (VIGOUR) with Shanghai MicroPort Rhythm MedTech Co., Ltd., 2023
  • NCT05659641 The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection(BROAD) with Permed Biomedical Engineering Co., Ltd, 2023

Evidence checked

485 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 334 of 819 candidate links were set aside.

Why links were set aside
  • 229 company name not written in the author's affiliation
  • 42 part of a university or public institute's own unit
  • 19 not an industry organisation
  • 8 excluded after hand audit: Matched from the Vanke School of Public Health and a street address
  • 8 refresh_university_not_on_work
  • 8 excluded after hand audit: Generic name matched from other company names
  • 20 for other reasons: smaller hand-audit findings, and links the current open record no longer supports

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

GRP Partnership Intelligence Platform

Where Hebei Medical University's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, Hebei Medical University ranks #1012 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.